Fresenius Medical Care reported strong financial results for the full year 2024, with operating income on an outlook base increasing by 18% to EUR 1,812 million, reaching the upper end of its tightened full-year outlook. Full-year revenue on an outlook base increased by 2% to EUR 19,454 million. The company's net leverage ratio improved to 2.9x at year-end 2024, down from 3.2x in 2023.
The FME25 transformation program delivered EUR 221 million in additional sustainable savings for 2024, surpassing the upgraded target of EUR 200 million. Accumulated savings for the program reached EUR 567 million, leading the company to raise its target for sustainable annual savings by EUR 100 million to EUR 750 million by the end of 2025. This reflects strong momentum in operational efficiency.
In a move to enhance shareholder value, Fresenius Medical Care proposed a dividend of EUR 1.44 per share for fiscal year 2024, representing a 21% increase compared to the prior year's dividend. This proposal aligns with the company's dividend policy of developing dividends in line with net income excluding special items. For 2025, the company expects revenue growth to be positive to a low-single digit percent rate and operating income to grow by a high-teens to high-twenties percent rate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.